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Key messages
What is already known about this subject?
 ► Use of a treat to target approach in the management 
of PsA can improve outcomes and is recommended 
internationally
 ► Routine implementation of a treat to target approach 
in PsA in most clinical settings is low
What does this study add?
 ► This review summarises the perceived barriers to 
implementation of a treat- to- target approach in PsA 
and identifies methodologies from implementation 
science that could be employed to change practice.
How might this impact on clinical practice?
 ► identification of perceived barriers by treating cli-
nicians will allow novel interventions to support a 
treat- to- target approach in PsA and change routine 
practice.
AbstrAct
with increasing recognition of the high burden and 
impact of psoriatic arthritis (PsA) and the growing number 
of therapeutic options, there has been an intensifying 
focus on treatment strategy in recent years. in 2015, 
the Tight Control of Psoriatic Arthritis study confirmed 
the clinical benefit of using a treat- to- target approach 
in PsA. This randomised controlled trial found benefits 
in both arthritis and psoriasis disease activity as well 
as lower disease impact reported by patients, although 
participants allocated to tight control experienced a higher 
rate of serious adverse events. european and international 
recommendations support the use of a treat- to- target 
approach in PsA and have offered specific advice on how 
to do this using outcomes such as the minimal disease 
activity criteria. However, implementation of this approach 
in routine practice is low, with real- world data highlighting 
undertreatment as a result. Recent qualitative work with 
physicians in the UK has helped researchers to understand 
the barriers to implementation of treat- to- target in PsA. we 
now need to address these barriers, provide education and 
support to non- specialist clinicians in routine practice, and 
aid the translation of optimal care to the clinic.
TreaTing To TargeT in Psa
Psoriatic arthritis (PsA) is a form of inflam-
matory arthritis affecting up to 30% of those 
with psoriasis. It is the second most common 
form of inflammatory arthritis presenting to 
early arthritis clinics and accounts for around 
20% of referrals. It has a considerable impact 
on patients’ functional capacity and quality 
of life,1 with two- thirds of those affected 
suffering progressive joint damage with asso-
ciated disability.2 3 PsA is also associated with 
a reduced life expectancy4 that is related to 
associated comorbidities, particularly meta-
bolic syndrome.5
With the recognition of high disease 
burden and impact in PsA, the focus has 
been on therapeutic options and treatment 
strategies to optimise care. As such, in the 
last decade, there has been an increase in the 
number of drugs approved for use in PsA, but 
there is limited evidence to guide the treat-
ment strategy. In rheumatoid arthritis (RA), 
the standard of care for over a decade has 
been to use a treat- to- target approach. This 
approach came initially from management of 
hypertension and diabetes, where improved 
outcomes were achieved through a treat- to- 
target strategy using regular review and esca-
lation of therapy according to a prespecified 
objective target.6 7 In RA, this was first tested 
in the Tight Control of Rheumatoid Arthritis 
study published in 20048 and several studies 
have subsequently confirmed these findings, 
and across Europe it is considered the stan-
dard of care in RA.9 In rheumatology, treat- 
to- target is considered an approach across 
clinical teams, with all clinicians including 
rheumatologists, trainees and allied health 
professionals such as specialist nurses able 
to implement the approach while caring for 
individuals with arthritis.
Following this lead, research in PsA has 
also addressed the treat- to- target concept. 
Minimal disease activity (MDA) criteria were 
developed using expert opinion on patient 
profiles and encompass disease activity 
measures across multiple disease domains 
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box 1 Minimal disease activity (MDa) criteria for 
psoriatic arthritis
The seven- component MDA criteria define a state of MDA if a patient 
meets five of the seven criteria10:
 ► Tender joint count ≤1.
 ► Swollen joint count ≤1.
 ► Psoriasis Area and Severity index ≤1 or body surface area ≤3.
 ► Patient Pain visual Analogue Score ≤15.
 ► Patient Global Disease Activity ≤20.
 ► Health Assessment Questionnaire ≤0.5.
 ► Tender entheseal points ≤1.
(box 1).10 The MDA criteria have been shown to have 
prognostic value in terms of quality of life,11 radiographic 
damage11–13 and work stability,11 and correspond highly 
with a level of symptoms that is acceptable to patients.14 15
Using the MDA criteria, the Tight Control of Psori-
atic Arthritis (TICOPA) trial was the first to demonstrate 
improved clinical and patient- reported outcomes, with a 
‘treat to target’ approach in PsA consisting of a 4- weekly 
treat- to- target review. The primary outcome was the 
proportion of patients achieving an American College of 
Rheumatology 20% (ACR20) response at week 48. The 
odds of achieving ACR20 (OR 1.91, p=0.0392), as well as 
ACR50, ACR70 and psoriasis area and severity index 75 
(PASI75), were significantly higher in the tight control 
group. Improvements in patient- reported outcomes, such 
as physical function (measured by the Health Assessment 
Questionnaire) and quality of life (measured by the PsA 
quality of life (PsAQOL)), were seen with tight control, 
although an increased rate of adverse events and serious 
adverse events was also noted in this group. This may be 
secondary to the use of combination therapies and rapid 
treatment escalation, or may partly reflect reporting bias 
from an unblinded trial due to more frequent clinical 
reviews.16 The results of this study led to the 2015 EULAR 
treatment recommendations for PsA incorporating as its 
first recommendation that ‘treatment should be aimed 
at reaching the target of remission or, alternatively, 
minimal/low disease activity, by regular monitoring and 
appropriate adjustment of therapy’.17 However, to date 
the TICOPA trial is the only study directly comparing a 
treat- to- target approach with standard care in PsA, and 
further evidence would be beneficial.
In addition to MDA, a number of other potential 
‘targets’ have been identified. Definitions of remission 
and low disease activity have been proposed for addi-
tional disease activity measures, including the Disease 
Activity in Psoriatic Arthritis (DAPSA) score,18 Psori-
atic Arthritis Disease Activity Score (PASDAS)19 and the 
Composite Psoriatic Disease Activity Index (CPDAI).19 
The DAPSA focuses on peripheral arthritis, while the 
PASDAS and CPDAI reflect disease activity in multiple 
domains similar to MDA. Achievement of these remis-
sion/low disease activity states has been shown to be 
associated with improved outcomes in terms of quality of 
life and radiographic progression.20 21
As yet, there is no international consensus on the 
optimal measure to use in a treat- to- target strategy, but 
only MDA has been tested in a treat- to- target strategy 
trial. In 2017, international recommendations that 
focused specifically on treat- to- target in spondyloarthritis 
(including PsA) were published. These were under-
pinned by a systematic literature review that included 
the TICOPA data. These recommendations confirm that 
treatment should be aimed at remission or alternatively 
minimal/low disease activity and specify that MDA is an 
approved outcome measure to use as a target in PsA. 
The Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA)- OMERACT recommenda-
tions support this view and favoured MDA over DAPSA as 
it reflected psoriasis and enthesitis in addition to periph-
eral joint disease.22
Unfortunately, despite this change in international 
treatment recommendations, a treat- to- target approach 
has not been translated into routine clinical practice.23 
An international survey in 2017 found that only 45% of 
healthcare professionals reported that they regularly use 
a composite measure required for treat- to- target in their 
practice, most commonly the MDA criteria or the Routine 
Assessment of Patient Index Data-3.22 This survey was 
distributed to members of the GRAPPA and therefore 
represents views of rheumatologists and other clinicians 
with a specialist interest in PsA. It should be expected 
that uptake of treat- to- target in routine practice could be 
even lower. A small UK- based survey in 2015 previously 
found that only around 10% of clinicians reported using 
a treat- to- target approach in PsA (LC Coates, unpub-
lished data).
To date, there has been relatively little focus on the 
implementation of treat- to- target in PsA apart from inclu-
sion in treatment recommendations. There have been 
some local educational initiatives to encourage clini-
cians to consider a treat- to- target approach and practical 
training on how to assess these outcomes, but they are 
not widespread. In contrast to RA,24 we are not aware of 
any national guidelines, such as those from the National 
Institute for Health and Care Excellence in the UK, that 
have recommended the use of a treat- to- target approach, 
so it may not have become a priority.
This failure of translation from trial results to imple-
mentation in clinical practice is preventing optimal care 
of people with PsA in many centres. Observational studies 
have provided insight into the discrepancy between clini-
cian opinion and objective measurement of a target. A 
study in the Netherlands found that two- thirds of patients 
whom the clinician felt were in an acceptable disease state 
did fulfil the MDA criteria, suggesting reasonable disease 
control when assessments were subsequently performed. 
The remaining one- third (88 of 250) of patients did not 
fulfil the MDA criteria, but the clinician reviewing them 
did not suggest an escalation in treatment. In the majority 
of cases, this discordance was driven by a high number 
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of tender joints, and high pain and patient global scores 
(83%, 82% and 80%, respectively), which may not always 
reflect disease activity. However, a significant propor-
tion of these patients also had objective disease activity 
evidenced by swollen joints (35%), enthesitis (14%) 
and skin psoriasis (43%),25 suggesting that non- clinical 
factors might also have a role in supporting the uptake of 
a treat- to- target approach.
Even in consultations where clinicians identify ongoing 
active disease, this does not often trigger a treatment 
change. In a second Dutch observational study, 63% 
(90 of 142) of patients were considered to have active 
disease, but a treatment change was only instituted in 
23% (21 of 90). The most common reason for this was 
that either that the clinician felt that the residual disease 
was not substantial enough to justify treatment adjust-
ment or that the patient did not wish to adjust treatment. 
However, when subsequent assessments were performed, 
patients without treatment adjustment had similar levels 
of disease activity, such as joint counts and patient scores, 
to those receiving treatment escalation. This suggests that 
more formal assessments of disease activity may identify 
active disease than is otherwise unappreciated in some 
routine consultations.26 There has been little research on 
patients’ opinions on a treat- to- target approach, and no 
research to date on whether educating patients about a 
treat- to- target approach may result in a change in their 
views about treatment escalation. While following a treat- 
to- target approach does not remove a treatment and 
management plan that is tailored to the individual, these 
data highlight the potential undertreatment of patients 
in routine practice when treat- to- target is not followed.
iMPleMenTaTion sCienCe
Implementation research was initially conceived to 
address the poor uptake of effective interventions, and 
thereby improve the quality and effectiveness of health 
services.27 Examples of implementation interventions 
include theory- informed interventions to support change 
in healthcare organisations, the behaviour of healthcare 
professionals or the use of health services by healthcare 
recipients.28 Effective interventions have been identi-
fied to support the implementation of the treat- to- target 
approach; for example, the Treat to target in RA: Collab-
oration To Improve adOption and adhereNce (TRAC-
TION) cluster randomised trial29 generated evidence 
of the effectiveness of a learning collaborative to train 
clinicians in using treat- to- target to guide treatment deci-
sions in RA. In this study, the learning collaborative was 
established with an initial 1- day meeting with education 
around treat- to- target in RA, followed by a workshop 
focused on activities planned by the study teams within a 
change package for treat- to- target implementation. Ideas 
for plan–do–study–act (PDSA) cycles were presented 
to the teams, and then within workshops study teams 
identified the cycles that they wanted to test locally. The 
PDSA cycles link to tests of change, in these four stages, 
performed as part of a quality improvement process.30
This study randomised 11 centres to receive the 
learning collaborative either in phase 1 of the study (0–9 
months) or in phase 2 (9–18 months). At baseline the 
treat- to- target implementation score was 11% in both 
arms. At the end of phase 1, the primary outcome of the 
study showed an increase in the treat- to- target implemen-
tation score of 46% in group 1 (receiving the interven-
tion) compared with 14% in group 2 (the control group) 
(p=0.004).31 The inclusion of a second phase allowed 
further assessment of the intervention when it was 
repeated for group 2, where success was hypothesised to 
be higher due to increased experience of the study team 
and sharing of phase 1 experiences. However, this was not 
confirmed and the phase 2 showed similar improvements 
in treat- to- target implementation scores. This second 
phase also allowed assessment of the ongoing mainte-
nance of a treat- to- target approach in group 1. Although 
implementation scores dropped slightly (from 57% to 
52%), maintenance of the approach was still impressive 
compared with baseline levels.32
inTervenTions iDenTifieD To suPPorT TreaT-To-TargeT
Clearly treat- to- target in PsA requires similar support to 
translate the approach into routine clinical practice. The 
first step in this process is to identify key barriers to imple-
mentation. A qualitative study in the UK has recently 
attempted to address this by conducting individual inter-
views and focus groups with clinicians caring for patients 
with PsA. Key barriers identified were complexity of the 
disease and interventions, and reluctance to change 
practice due to organisational factors.33 The complexity 
theme included three aspects:
 ► ‘PsA vs RA’: compared with treat- to- target in RA, 
application in PsA is seen as underfunded and more 
complex to implement given the heterogeneity of the 
condition and the number of disease domains that 
require treatment.
 ► ‘Measurement’: the perceived challenges of agreeing 
on the measures to be used and the processes for data 
collection and storage.
 ► ‘Resources’: team needs, including training to use 
and interpret measures, and organisational support, 
including PsA- specific clinics.
Thus, it seems that to enable implementation, multiple 
factors need to be addressed. Education of clinicians 
caring for patients with PsA on the need for treat- to- 
target and the assessment of disease activity in PsA will 
address some of these barriers. In particular within the 
focus group, rheumatology trainees raised the issue of 
training around assessment and treatment advice for 
psoriasis where they felt that they lacked confidence. 
However, a significant gap in implementation relates to 
the process of care, both engagement and organisational 
factors, not just a lack of education. Developing practical 
clinical protocols, sharing successful approaches and 
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learning from others’ experiences may also be beneficial 
in improving implementation. Feedback with regular 
audit within practices may also support implementation, 
allowing clinicians to evaluate strategies and share best 
practice. This approach was used within the learning 
collaborative in the TRACTION study in RA with great 
success.
In terms of health service organisation, it is possible that 
specialist PsA clinics might be advantageous. These allow 
the clinicians to develop expertise, focus on PsA- specific 
measures and give a practical advantage where clinic 
support staff can more easily ask patients to complete 
questionnaires. In other rheumatological conditions, 
dedicated clinics for complex disease have been shown to 
not only facilitate systematic clinical assessments but also 
to result in higher quality of care.34 This approach might 
be cost- neutral for healthcare services, if using the same 
staff and appointment templates as seeing patients with 
PsA among those with a variety of different musculoskel-
etal conditions within a ‘general rheumatology’ clinic. 
However, we recognise that this approach might not be 
possible in smaller centres or in centres without a clini-
cian with a specialist interest in PsA, where additional 
logistical help may be able to support implementation.
Many clinicians raised concerns about the resources 
required to implement the treat- to- target approach 
routinely. In limited duration routine appointments, 
typically lasting 15–20 min, clinicians find it challenging 
to collect and administer the appropriate disease activity 
measures, calculate the MDA components and record the 
data appropriately. In situations where routine appoint-
ments are even shorter, the pressures are greater. Given 
the increasing availability of electronic patient records 
and information technology (IT) systems in hospital 
clinics, it seems likely that an IT solution may be able 
to help and make this more efficient. Several electronic 
patient record systems internationally, such as Epic and 
Cerner, provide the opportunity for patients to complete 
information, including the patient- reported outcomes 
required for treat- to- target, either remotely prior to their 
appointment or within the clinic via app, email or touch-
screen. These systems can also calculate scores required 
for the outcomes to aid the assessment of the MDA 
criteria.
Although not identified in the study of clinicians’ views, 
support from patients will also be crucial. Providing 
patients with information about treat- to- target and the 
opportunity to discuss the options with their team can 
enable them to participate in treatment decisions and 
could increase their engagement with the process, 
including completing the patient- reported outcomes. It 
may also aid implementation by changing the expecta-
tion of the patient when they see their clinicians.
nexT sTePs
Given the promising evidence of improved health 
outcomes for people with PsA from treat- to- target in the 
TICOPA trial, and the low uptake of this approach in 
clinical practice, further research on how to effectively 
implement treat- to- target has the potential to increase 
the number of people with PsA who will benefit. As 
TICOPA is the only study to directly assess a treat- to- 
target approach in PsA, further studies addressing this 
strategy would also be beneficial. Studies that identify the 
barriers experienced by clinicians to implementing treat- 
to- target in PsA will provide evidence to guide the design 
of theory- based interventions that will support the imple-
mentation of this approach in practice. Evidence from 
the TRACTION study in RA indicates that such interven-
tions can be successful and maintained beyond the initial 
study period.
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